Deflector-type micro-capsule suspension type fluidized bed bioreactor for artificial liver

Abstract

The invention discloses a deflector-type micro-capsule suspension type fluidized bed bioreactor for an artificial liver. The deflector-type micro-capsule suspension type fluidized bed bioreactor for the artificial liver comprises an end cover part, a main body part and a base part, wherein the base part comprises an inlet buffer tank, a fixed turbine guide vane, and an inlet filter net arranged at the joint surface of the base part and a subject part; the main body part comprises a cylindrical containing cavity, a sampling and micro-capsule pouring lip and a valve; the sampling and micro-capsule pouring lip and the valve are arranged in a housing of the main body part; and the top cover part comprises an outlet buffer tank, and an outlet filter net arranged at the joint surface of the subject part and the top cover part. By adopting the sealed structure and a multi-opening design, the microencapsulated hepatocyte can be conveniently sampled and added; and meanwhile, the possibility of pollution in an operation process is reduced. The turbine guide vane of the base part can disperse large local flow speed at the inlet; micro-capsule damage is reduced; and the blood purification efficiency is improved. By adopting the deflector-type micro-capsule suspension type fluidized bed bioreactor for the artificial liver, the contact efficiency of the cultivated cell in the bioreactor and perfusate can be improved; meanwhile, the cyclic purification efficiency of the biological part in an artificial liver system is improved; and clinic application is facilitated.

Description

technical field [0001] The invention belongs to the technical field of biomedicine and relates to a medical device, which is a core device of a specific biological artificial liver or a hybrid artificial liver. Background technique [0002] The bioreactor is the core device of the bioartificial liver system or hybrid artificial liver system. Its main function is to have sufficient capacity and efficiency to provide patient plasma and exogenous liver cells for material exchange, and at the same time, it needs to have the ability of immune isolation . The type of bioreactor that has been researched hotspots in the past and has entered clinical trials is mainly a hollow fiber reactor, but it has disadvantages such as uneven cell distribution, low cell adhesion rate and activity, and semipermeable membrane blockage. At the same time, it has been found that microencapsulated hepatocytes have potential value for bioartificial livers—the shell of the microcapsules that wrap th...

AI Technical Summary

Problems solved by technology

In response to these shortcomings, our laboratory has developed a microcapsule suspension fluidized bed bioreactor for artificial liver (patent number: ZL 200820167026.5) and a supporting dual-chamber liquid storage tank for bioartificial liver support system (patent number: ZL 200710070279.0), and built a new type of bioartificial liver system based on it. Animal experiments showed that the system has good curative effect, but also found that it still needs to be perfected and improved: 1. The reactor needs more Only a high liquid flow rate can make the microencapsulated hepatocytes fully suspended and fluidized, but the fluid shear force that the microcapsules that wrap ...

Images